Computational prediction of ADMET properties of ACAT inhibitors for synthesis and pharmacological screening
Shainda Laeeq, Vishal Dubey · International Journal of Health Sciences · 2022
As we know ACAT enzyme is responsible for the catalysis of cholesterol into cholesteryl esters leading to Hyperlipidemia which is directly linked with cardiac problems. Throughout the world cardiac problems are causing increased mortality. This study aims to synthesize and screen pharmacologically active compound from the best five compounds docked having good binding affinity found in our earlier research against ACAT enzyme. The compounds were detected for their ADME value by SwissADME software and checked the toxicity level via ProTox-II server showing the antihyperlipidemic effect against ACAT enzyme. For pharmacological screening rats were fed with High Fat Diet and then evaluated by Atorvastatin (10 mg/kg) which was used as standard drug and the test compound. Blood samples were collected at 28th day. Serum was separated and then analyzed for lipid profile, using standard diagnostic reagent kits. The results demonstrated that the synthetic drug C10 raised the concentration of high-density lipoprotein in serum while lowering the total cholesterol, triglycerides, and low-density lipoprotein. C10 compound possess antihyperlipidemic activity.